Autologous BM-MSCs and Islet Co-transplantation to Enhance Islet Survival and Function in TP-IAT Patients
自体 BM-MSC 和胰岛联合移植可增强 TP-IAT 患者的胰岛存活和功能
基本信息
- 批准号:10315988
- 负责人:
- 金额:$ 63.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-24 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse eventAllogenicAnimalsArea Under CurveAutologousAutologous TransplantationBeta CellBone MarrowC-PeptideCell Culture TechniquesCell DeathCell SurvivalCellsClinical ResearchClinical TrialsComplement Factor BComplexConstitutionCyclic GMPCytoprotectionDNADataDiabetes MellitusDiseaseDoseEngraftmentEnzyme-Linked Immunosorbent AssayFlow CytometryFunctional disorderFundingGene ExpressionGoalsGrantGrowth FactorHGF geneHumanImmune responseInflammatoryInfusion proceduresInsulinInsulin-Dependent Diabetes MellitusInterventionIslet CellIslets of Langerhans TransplantationMeasuresMediator of activation proteinMesenchymalMesenchymal Stem CellsMicroRNAsModelingNatureOperative Surgical ProceduresPatient RecruitmentsPatientsPreventionProductionProtocols documentationQuality of lifeRandomized Controlled Clinical TrialsResearchRodentSafetySerumTestingTherapeuticTotal PancreatectomyTransforming Growth FactorsTranslatingTransplant RecipientsTransplantationUnited States National Institutes of Healthbasebench to bedsidechemokinechronic pancreatitiscytokineeffective therapyexperienceglycemic controlimprovedinsightisletmolecular markermonocytenon-diabeticnonhuman primatepain reliefparacrinepatient populationpost-transplantprimary endpointresponsesecondary endpointsingle-cell RNA sequencingstem cell therapystem cellstransplant model
项目摘要
Project Summary:
Total pancreatectomy and islet autotransplantation (TP-IAT) are currently performed in around 20 centers
worldwide for the treatment of chronic pancreatitis (CP). Major problems associated with TP-IAT are poor islet
engraftment and dysfunction after intraportal infusion. Because of these issues, only around 20% of the non-
diabetic CP patients are insulin-independent after surgery. Currently, interventional protocols to increase the
survival of the islet graft following transplantation are empiric. Thus, effective therapies that can facilitate islet
cell engraftment and promote survival after transplantation are urgently needed.
Multiple studies including our own demonstrate that islet co-transplantation with mesenchymal stem cells (MSCs)
enhances islet engraftment, decreases number of islets needed to achieve normoglycemia in rodent and
nonhuman primate islet transplantation models. MSCs exert such effects mainly via direct cell-cell contact and
their paracrine secretion of protective molecules including insulin growth factor-1 (IGF-1), hepatocyte growth
factor (HGF), transforming growth factor β (TGF- β) and others. We are the first group who performed a pilot
NIH-funded clinical trial evaluating the feasibility of autologous bone marrow-derived ex vivo-expanded MSCs
(BM-MSCS) and islet co-transplantation in CP patients. Although only three subjects received MSC and islet co-
transplantation due to the pilot nature of the grant, our data showed that BM-MSCs and islet co-transplantation
was a safe and promising strategy to improve islet engraftment after transplantation. Based on this unique clinical
trial experience and animal studies, the goal of this study is to further evaluate the safety and efficacy of
autologous MSCs and islet co-transplantation in a larger TP-IAT patient population. Our hypothesis is that co-
transplantation of islets with autologous BM-MSCs can enhance islet survival and function after transplantation,
resulting in more CP patients being diabetes free after TP-IAT. A critical part of this trial will be to define the
mechanisms by which MSCs modulate β cell survival and explore cellular and molecular biomarkers that can be
used as indicator(s) for β cell death and the potential response/efficacy of MSC therapy. Results from these
studies are not only urgently needed for the prevention of post-surgical diabetes in CP patients, but also may
offer useful information on which to address the more complex allogeneic islet cell transplantation for patients
with type 1 diabetes.
项目总结:
全胰腺切除和自体胰岛移植(TP-IAT)目前在大约20个中心进行
全球用于治疗慢性胰腺炎(CP)。与TP-IAT相关的主要问题是较差的胰岛
门脉内输液后的植入和功能障碍。由于这些问题,只有大约20%的非
糖尿病慢性胰腺炎患者术后胰岛素非依赖性。目前,介入性协议增加了
移植后胰岛移植物的存活率是经验性的。因此,有效的治疗方法可以促进胰岛
移植后迫切需要细胞植入和促进存活。
包括我们自己在内的多项研究表明,胰岛与间充质干细胞(MSCs)联合移植
增强胰岛植入,减少达到正常血糖所需的胰岛数量,并
非人灵长类胰岛移植模型。MSCs主要通过细胞与细胞之间的直接接触发挥这种作用
他们旁分泌保护性分子包括胰岛素生长因子-1(IGF-1),肝细胞生长
转化生长因子β、转化生长因子β等。我们是第一个表演试演的团体
美国国立卫生研究院资助的临床试验评估自体骨髓来源体外扩增间充质干细胞的可行性
骨髓间充质干细胞与胰岛联合移植治疗慢性阻塞性肺疾病虽然只有三名受试者接受了MSC和胰岛联合移植-
由于移植的试点性质,我们的数据显示,BM-MSCs和胰岛联合移植
是提高移植后胰岛植入率的一种安全而有前景的策略。基于这一独特的临床
试验经验和动物研究,本研究的目的是进一步评估阿司匹林的安全性和有效性。
自体骨髓间充质干细胞和胰岛联合移植在更大的TP-IAT患者群体中的应用。我们的假设是联合-
自体BM-MSCs移植胰岛可提高移植后胰岛的存活率和功能。
导致更多的CP患者在TP-IAT后无糖尿病。这项试验的一个关键部分将是定义
间充质干细胞调节β细胞存活的机制和探索细胞和分子生物标志物可以
作为β细胞死亡和骨髓间充质干细胞治疗的潜在反应/疗效的指标(S)。来自这些的结果
不仅迫切需要研究预防脑瘫患者术后糖尿病,而且还可能
为患者解决更复杂的同种异体胰岛细胞移植提供有用的信息
患有1型糖尿病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hongjun Wang其他文献
Hongjun Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hongjun Wang', 18)}}的其他基金
Safety and Efficacy of Mesenchymal Stem Cells in the Treatment of Chronic Pancreatitis and Its Associated Pain
间充质干细胞治疗慢性胰腺炎及其相关疼痛的安全性和有效性
- 批准号:
10721284 - 财政年份:2023
- 资助金额:
$ 63.22万 - 项目类别:
Autologous BM-MSCs and Islet Co-transplantation to Enhance Islet Survival and Function in TP-IAT Patients
自体 BM-MSC 和胰岛联合移植可增强 TP-IAT 患者的胰岛存活和功能
- 批准号:
10474572 - 财政年份:2021
- 资助金额:
$ 63.22万 - 项目类别:
Autologous BM-MSCs and Islet Co-transplantation to Enhance Islet Survival and Function in TP-IAT Patients
自体 BM-MSC 和胰岛联合移植可增强 TP-IAT 患者的胰岛存活和功能
- 批准号:
10640946 - 财政年份:2021
- 资助金额:
$ 63.22万 - 项目类别:
hAAT-engineered Mesenchymal Stem Cells for the Treatment of Chronic Pain
hAAT 工程改造的间充质干细胞用于治疗慢性疼痛
- 批准号:
10292900 - 财政年份:2019
- 资助金额:
$ 63.22万 - 项目类别:
hAAT-engineered Mesenchymal Stem Cells for the Treatment of Chronic Pain
hAAT 工程改造的间充质干细胞用于治疗慢性疼痛
- 批准号:
10044402 - 财政年份:2019
- 资助金额:
$ 63.22万 - 项目类别:
hAAT-engineered Mesenchymal Stem Cells for the Treatment of Chronic Pain
hAAT 工程改造的间充质干细胞用于治疗慢性疼痛
- 批准号:
10515305 - 财政年份:2019
- 资助金额:
$ 63.22万 - 项目类别:
Cellular Therapy for Type 1 Diabetes using Mesenchymal Stem Cells
使用间充质干细胞进行 1 型糖尿病的细胞疗法
- 批准号:
10599910 - 财政年份:2019
- 资助金额:
$ 63.22万 - 项目类别:
Cellular Therapy for Type 1 Diabetes using Mesenchymal Stem Cells
使用间充质干细胞进行 1 型糖尿病的细胞疗法
- 批准号:
10376342 - 财政年份:2019
- 资助金额:
$ 63.22万 - 项目类别:
Micro- and nanofiber enabled biomimetic periosteum for bone repair and reconstruction
微米和纳米纤维仿生骨膜用于骨修复和重建
- 批准号:
9026932 - 财政年份:2016
- 资助金额:
$ 63.22万 - 项目类别:
Micro- and nanofiber enabled biomimetic periosteum for bone repair and reconstruction
微米和纳米纤维仿生骨膜用于骨修复和重建
- 批准号:
9755362 - 财政年份:2016
- 资助金额:
$ 63.22万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 63.22万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 63.22万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 63.22万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 63.22万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 63.22万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 63.22万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 63.22万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 63.22万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 63.22万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 63.22万 - 项目类别: